-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$1.00-29.58% Downside
Nabriva Therapeutics plc Frequently Asked Questions
-
What analysts cover Nabriva Therapeutics plc?
Nabriva Therapeutics plc has been rated by research analysts at Northland Securities in the past 90 days.